Home Cart Sign in  
Chemical Structure| 313380-27-7 Chemical Structure| 313380-27-7

Structure of FDI-6
CAS No.: 313380-27-7

Chemical Structure| 313380-27-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FDI-6 is an inhibitor of FOXM1 that block DNA binding. It act by specifically downregulating FOXM1-activated genes.

Synonyms: NCGC00099374

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FDI-6

CAS No. :313380-27-7
Formula : C19H11F4N3OS2
M.W : 437.43
SMILES Code : O=C(C1=C(N)C2=C(C(F)(F)F)C=C(C3=CC=CS3)N=C2S1)NC4=CC=C(F)C=C4
Synonyms :
NCGC00099374
MDL No. :MFCD01416826
InChI Key :ZATJMMZPGVDUOM-UHFFFAOYSA-N
Pubchem ID :5175738

Safety of FDI-6

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P280-P301+P312+P330-P305+P351+P338-P337+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 breast cancer cells 21.8 μM (GI50) 3 h After FDI-6 treatment, CDC25B expression was down-regulated. PMC4258842
PEO-1 ovarian cancer cells 18.1 μM (GI50) 3 h After FDI-6 treatment, CDC25B expression was down-regulated. PMC4258842
LX-2 cells 5 μM 24 h reduced mRNA and protein levels of FOXM1, MATα2, MAT2β, α-SMA, and COL1A1 PMC11436801
hepatic stellate cells (HSCs) 5 μM 24 h reduced mRNA and protein levels of FOXM1, MATα2, MAT2β, α-SMA, and COL1A1 PMC11436801
MCF-7 breast cancer cells 20 μM 6 h After FDI-6 treatment, chromatin-bound FOXM1 decreased by nearly 50%, while the total amount of FOXM1 protein remained unaffected. PMC4258842
Human cord blood CD34+ hematopoietic stem/progenitor cells 10 μM 5 days To investigate the inhibitory effect of FDI-6 on FOXM1 transcriptional activity and its impact on erythropoiesis. Results showed that FDI-6 treatment increased CD71+ and CD71+/GlyA+ cell populations, indicating enhanced proliferation of erythroid precursors. PMC5477601
MDA-MB-468 cells 4.0 μM 7 days FDI-6 and Olaparib synergistically inhibited cell proliferation and promoted apoptosis. PMC8654856
MDA-MB-231 cells 4.0 μM 7 days FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient TNBC cells to Olaparib by blocking cell cycle progression and DNA damage repair. PMC8654856
Mouse retinal microvascular endothelial cells (MRMECs) 0, 1, 2.5, 5, 10, 20, 30, 40, 60 μM 24 h To assess the cytotoxicity and anti-proliferative ability of FDI-6 in MRMECs. Results showed that FDI-6 had no toxic effects on MRMECs at concentrations of 0 to 5 μM and induced cytotoxicity at concentrations of 10 to 60 μM. PMC9034725
Murine macrophages (RAW264.7 cells) 0, 2.5, 5, 10, 20, 40, 60 μM 24 h To assess the cytotoxicity and anti-proliferative ability of FDI-6 in RAW264.7 cells. Results showed that FDI-6 induced cytotoxicity at concentrations exceeding 10 μM, and cell proliferation was unaffected at concentrations of 0 to 10 μM. PMC9034725
MDA-MB-231 cells 10.8 μM (IC50,) 24h Evaluate the effect of FDI-6 on cell viability, showing an IC50 of 10.8 μM after 24h treatment PMC11909019
HUVEC cells 24.2 μM (IC50) 24h Evaluate the effect of FDI-6 on cell viability, showing an IC50 of 24.2 μM after 24h treatment PMC11909019

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Diabetic mouse models (STZ-induced and db/db) Topical administration 150 µM Every 2 days for 8 days Inhibition of FOXM1 resulted in delayed wound healing and decreased recruitment of neutrophils and macrophages in diabetic wounds PMC7495445
Male mice CCl4-induced liver fibrosis model Intraperitoneal injection 25 mg/kg Three times per week for two weeks FDI-6 significantly attenuated the development of CCl4-induced liver fibrosis and reversed already established fibrosis, lowering the expression of FOXM1, MAT2A, MAT2B, α-SMA, F4/80, and COL1A1 PMC11436801
BALB/C nude mice MDA-MB-231 xenograft model Intraperitoneal injection 30 mg/kg 28 consecutive days FDI-6 and Olaparib synergistically inhibited tumor growth and suppressed the expression of FOXM1 and PARP1/2. PMC8654856
Sprague Dawley rats Corneal alkali burn model Subconjunctival injection and topical application 40 μM,20μL 4 times daily for 7 days To evaluate the inhibitory effects of FDI-6 on alkali burn-induced corneal inflammation, neovascularization, and fibrosis. Results showed that FDI-6 significantly attenuated corneal inflammation, neovascularization, and fibrosis. PMC9034725

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.43mL

2.29mL

1.14mL

22.86mL

4.57mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories